谢方云

一、基本情况

职称：教授、主任医师、博士生导师

专业特长：头颈部肿瘤尤其是鼻咽癌的临床诊断、放射治疗及综合治疗。

专家门诊时间：越秀院区：周二下午、周三上午 黄埔院区：周四上午

主攻方向如下：①证明了TPF、GP及卡培他滨维持化疗等方案在鼻咽癌的有效性，成果分别发表在Lancet Oncology、NEJM、Lancet等肿瘤学顶尖期刊，改写了鼻咽癌的国际治疗指南；②正在承担初诊转移鼻咽癌的免疫治疗联合放疗的临床研究；③我院头颈部肿瘤放疗大PI，广东省医师协会放疗专业委员会头颈组组长，在头颈肿瘤的调强放射治疗及综合治疗已有30余年的诊治经验。

二、学习及工作经历

1980.09-1985.07  湖南医学院（现中南大学湘雅医学院）   临床医学  获学士学位

1985.07-2002.08 中山大学肿瘤防治中心  放疗科 住院医师、主治医师

1990.09-1994.07  中山医科大学   肿瘤学  获硕士学位

2002.08-至今 中山大学肿瘤防治中心  放疗科 副主任医师、主任医师、教授

三、学术兼职

广东省医师协会放射治疗专业委员会副主任委员

广东省医师协会放射治疗专业委员会头颈肿瘤专业组组长

广东省临床医学学会头颈肿瘤综合治疗专业委员会副主任委员

中国临床肿瘤学会（CSCO）鼻咽癌专业委员会委员

粤港澳大湾区放射治疗医师联盟副主任

中国肿瘤放射治疗联盟放射免疫工作委员会副主任委员

中国肿瘤放射治疗联盟放射免疫工作委员会广东分会主任委员

四、获奖情况

(1) 鼻咽癌综合诊疗方案的创立与临床应用 2021年 广东省科技进步一等奖

(2) 鼻咽癌精准诊疗方案的建立与应用 2020年 教育部高校科技进步奖一等奖

(3) 提高鼻咽癌疗效的关键技术与应用 2020年 广东省医学科学技术奖一等奖

(4) 鼻咽癌诊疗关键策略研究与应用  2015年 国家科学技术进步奖二等奖

(5) 鼻咽癌个体化治疗研究与应用 2014年 中华医学科技奖一等奖

(6) 鼻咽癌个体化治疗研究与应用 2014年 高等教育部科技进步奖一等奖

(7) 鼻咽癌个体化治疗研究与应用 2014年 广东省科学技术奖励一等奖

五、主持科研项目

①国家自然科学基金重点项目 cdh1(FZR1)磷酸化新点被调控的机理，对功能的影响及其意义(2009-2013年，第2负责人)

②国家自然科学基金面上项目  Fli-1靶向上调VEGF-C促进鼻咽癌转移的分子机制和临床意义研究（2017-2020年 第1负责人）

③广东省自然科学基金 Fli-1靶向调控VEGF-C促进鼻咽癌生长和转移的研究（2017-2020，第1负责人）

④广东省科学技术厅 多西他赛加顺铂（TP）对比单药顺铂（DDP）的同期化疗联合调强放疗治疗高危局部区域晚期鼻咽癌的随机对照II期临床研究（2016-2018年，第1负责人）

⑤中山大学5010项目 调强放疗加或不加同期化疗治疗II期鼻咽癌的非劣效性、随机对照、多中心III期临床研究（2015-2025年，第1负责人）

六、第一及或通讯作者发表SCI文章

1.Chen YP, Liu X, Zhou Q, Yang KY, Jin F, Zhu XD, Shi M, Hu GQ, Hu WH, Sun Y, Wu HF, Wu H, Lin Q, Wang H, Tian Y, Zhang N, Wang XC, Shen LF, Liu ZZ, Huang J, Luo XL, Li L, Zang J, Mei Q, Zheng BM, Yue D, Xu J, Wu SG, Shi YX, Mao YP, Chen L, Li WF, Zhou GQ, Sun R, Guo R, Zhang Y, Xu C, Lv JW, Guo Y, Feng HX, Tang LL, Xie FY*, Sun Y, Ma J. Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial. Lancet. 2021 Jun 4:S0140-6736(21)01123-5.(IF 168.9)

2.Zhang Y, Chen L, Hu GQ, Zhang N, Zhu XD, Yang KY, Jin F, Shi M, Chen YP, Hu WH, Cheng ZB, Wang SY, Tian Y, Wang XC, Sun Y, Li JG, Li WF, Li YH, Tang LL, Mao YP, Zhou GQ, Sun R, Liu X, Guo R, Long GX, Liang SQ, Li L, Huang J, Long JH, Zang J, Liu QD, Zou L, Su QF, Zheng BM, Xiao Y, Guo Y, Han F, Mo HY, Lv JW, Du XJ, Xu C, Liu N, Li YQ, Chua MLK, Xie FY*, Sun Y, Ma J. Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma. N Engl J Med. 2019 Sep 19;381(12):1124-1135. (IF 158.5)

3.Mao YP, Wang SX, Gao TS, Zhang N, Liang XY, Xie FY*, Zhang Y, Zhou GQ, Guo R, Luo WJ, Li YJ, Liang SQ, Lin L, Li WF, Liu X, Xu C, Chen YP, Lv JW, Huang SH, Liu LZ, Li JB, Tang LL, Chen L, Sun Y, Ma J. Medial retropharyngeal nodal region sparing radiotherapy versus standard radiotherapy in patients with nasopharyngeal carcinoma: open label, non-inferiority, multicentre, randomised, phase 3 trial. BMJ. 2023 Feb 6;380:e072133. (IF 105.7)

4.P.Y.OuYang,C.Xie,Y.P.Mao,Y.Zhang,X.X.Liang,Z.Su,Q.Liu&F.Y.Xie*. Significant efficacies of neoadjuvant and adjuvant chemotherapy for nasopharyngeal carcinoma by meta-analysis of published literature-based randomized, controlled trials. Ann Oncol 2013;24:2136-2146(IF 51.769)

5.Sun Y, Li WF, Chen NY, Zhang N, Hu GQ, Xie FY*, Sun Y, Chen XZ, Li JG, Zhu XD, Hu CS, Xu XY, Chen YY, Hu WH, Guo L, Mo HY, Chen L, Mao YP, Sun R, Ai P, Liang SB, Long GX, Zheng BM, Feng XL, Gong XC, Li L, Shen CY, Xu JY, Guo Y, Chen YM, Zhang F, Lin L, Tang LL, Liu MZ, Ma J. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial. Lancet Oncol. 2016 Nov;17(11):1509-1520.(IF 51.1)

6.Zhang Y, Chen L, Hu GQ, Zhang N, Zhu XD, Yang KY, Jin F, Shi M, Chen YP, Hu WH, Cheng ZB, Wang SY, Tian Y, Wang XC, Sun Y, Li JG, Li WF, Li YH, Mao YP, Zhou GQ, Sun R, Liu X, Guo R, Long GX, Liang SQ, Li L, Huang J, Long JH, Zang J, Liu QD, Zou L, Su QF, Zheng BM, Xiao Y, Guo Y, Han F, Mo HY, Lv JW, Du XJ, Xu C, Liu N, Li YQ, Xie FY*, Sun Y, Ma J, Tang LL. Final Overall Survival Analysis of Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma: A Multicenter, Randomized Phase III Trial. J Clin Oncol. 2022 Jun 16:JCO2200327. (IF 45.3)

7.OuYang PY, You KY, Zhang LN, Xiao Y, Zhang XM, Xie FY*. External validity of a prognostic nomogram for locoregionally advanced nasopharyngeal carcinoma based on the 8th edition of the AJCC/UICC staging system: a retrospective cohort study. Cancer Commun (Lond). 2018 Sep 3;38(1):55. (IF 16.2)

8.OuYang PY, Zhang BY, Guo JG, Liu JN, Li J, Peng QH, Yang SS, He Y, Liu ZQ, Zhao YN, Li A, Wu YS, Hu XF, Chen C, Han F, You KY, Xie FY*. Deep learning-based precise prediction and early detection of radiation-induced temporal lobe injury for nasopharyngeal carcinoma. EClinicalMedicine. 2023 Apr 4;58:101930.(IF 15.3)

9.OuYang PY, He Y, Guo JG, Liu JN, Wang ZL, Li A, Li J, Yang SS, Zhang X, Fan W, Wu YS, Liu ZQ, Zhang BY, Zhao YN, Gao MY, Zhang WJ, Xie CM, Xie FY*. Artificial intelligence aided precise detection of local recurrence on MRI for nasopharyngeal carcinoma: a multicenter cohort study. EClinicalMedicine. 2023 Aug 30;63:102202. doi: 10.1016/j.eclinm.2023.102202. (IF 15.3)

10.OuYang PY, Liu ZQ, Lin QG, He Y, Guo ZX, Yao WY, Xu SK, Peng QH, Xiao SM, Li J, Li A, Zhang BY, Yang SS, Fan W, Xie CM, Wu YS, Zhang X, Chen CY, Xie FY*. Benefit of [18F] FDG PET/CT in the diagnosis and salvage treatment of recurrent nasopharyngeal carcinoma. Eur J Nucl Med Mol Imaging. 2023 Feb;50(3):881-891. (IF 9.1)

11.Yang SS, Wu YS, Chen WC, Zhang J, Xiao SM, Zhang BY, Liu ZQ, Chen EN, Zhang X, OuYang PY, Xie FY*. Benefit of [18F]-FDG PET/CT for treatment-naïve nasopharyngeal carcinoma. Eur J Nucl Med Mol Imaging. 2022 Feb;49(3):980-991.(IF 9.1)

12.Chen E, Huang J, Chen M, Wu J, Ouyang P, Wang X, Shi D, Liu Z, Zhu W, Sun H, Yang S, Zhang B, Deng W, Qiu H, Xie F*. FLI1 regulates radiotherapy resistance in nasopharyngeal carcinoma through TIE1-mediated PI3K/AKT signaling pathway. J Transl Med. 2023 Feb 22;21(1):134. doi: 10.1186/s12967-023-03986-y. (IF 7.4)

13.Yang SS, OuYang PY, Guo JG, Cai JJ, Zhang J, Peng QH, He Y, Zhang BY, Liu ZQ, Hu XF, Chen YF, Chen CY, Xie FY*. Dosiomics Risk Model for Predicting Radiation Induced Temporal Lobe Injury and Guiding Individual Intensity-Modulated Radiation Therapy. Int J Radiat Oncol Biol Phys. 2023 Apr 1;115(5):1291-1300. (IF 7)

14.P-Y OuYang, L-N Zhang, X-W Lan, C Xie, W-W Zhang, Q-X Wang, Z Su, J Tang and F-Y Xie*. The significant survival advantage of female sex in nasopharyngeal carcinoma:a propensity-matched analysis. Br J Cancer 2015;112:1554-1561(IF 6.176)

15.P-Y OuYang, Z Su, Y-P Mao, Q Liu and F-Y Xie*. Prognostic value of ABO blood group in southern Chinese patients with established nasopharyngeal carcinoma. Br J Cancer 2013;109:2462-2466(IF 6.176)

16.Pu-Yun OuYang, Zhen Su, Yan-Ping Mao, Xue-Xia Liang, Qing Liu, Wu-Guo Deng, and Fang-Yun Xie*. Prognostic impact of family history in southern Chinese patients with undifferentiated nasopharyngeal carcinoma. Br J Cancer 2013;109:788-794(IF 6.176)

17.P-Y OuYang, Z Su,X-H Ma, Y-P Mao, M-Z Liu and F-Y Xie*. Comparison of TNM staging systems for nasopharyngeal carcinoma, and proposal of a new staging system. Br J Cancer 2013;109:2987-29979(IF 6.176)

18.P-Y OuYang, Z Su, Y-P Mao, X-X Liang, Q Liu and F-Y Xie*. Prognostic impact of cigarette smoking on the survival of patients with established nasopharyngeal carcinoma.Cancer Epidemiol Biomarkers Prev 2013;22:2285-2294(IF 6.176)

19.Yang SS, Wu YS, Pang YJ, Xiao SM, Zhang BY, Liu ZQ, Chen EN, Zhang X, OuYang PY, Xie FY*. Development and validation of radiologic scores for guiding individualized induction chemotherapy in T3N1M0 nasopharyngeal carcinoma. Eur Radiol. 2022 Jun;32(6):3649-3660.(IF 5.9)

20.Yang SS, Guo JG, Liu JN, Liu ZQ, Chen EN, Chen CY, OuYang PY, Han F, Xie FY*. Effect of Induction Chemotherapy in Nasopharyngeal Carcinoma: An Updated Meta-Analysis. Front Oncol. 2021 Jan 8;10:591205.(IF 5.738)

21.Liu ZQ, Feng YF, Xiao Y, Zhang XM, Li JB, Xie FY*, Mao YP. Clinical characteristics, prognostic factors, and treatment modalities for head and neck lymphoepithelioma-like carcinoma: A real-world study from southern China. Radiother Oncol. 2023 Oct;187:109814. doi: 10.1016/j.radonc.2023.109814. (IF 5.7)

22.OuYang PY, Zhang XM, Qiu XS, Liu ZQ, Lu L, Gao YH, Xie FY*. A Pairwise Meta-Analysis of Induction Chemotherapy in Nasopharyngeal Carcinoma. Oncologist. 2019 Apr;24(4):505-512.(IF 5.306)

23.Pu-Yun OuYang, Dingbo Shi, Rui Sun, Yu-Jia Zhu, Yao Xiao,Lu-Ning Zhang, Xu-Hui Zhang, Ze-Ying Chen, Xiao-Wen Lan, Jie Tang, Yuan-Hong Gao, Jun Ma, Wuguo Deng, Fang-Yun Xie*. Effect of intensity-modulated radiotherapy versus two-dimensional conventional radiotherapy alone in nasopharyngeal carcinoma. Oncotarget. 2016 Apr 4.(IF 5.168)

24.Lu-Ning Zhang, Yuan-Hong Gao, Xiao-Wen Lan, Jie Tang, Zhen Su, Jun Ma, Wuguo Deng,Pu-Yun OuYang, Fang-Yun Xie*. Propensity score matching analysis of cisplatin-based concurrent chemotheraoy in low risk nasopharyngeal carcinoma in the intensity-modulated radiotheraphy era. Oncotarget 2015;6:44019-44029(IF 5.168)

25.Pu-Yun OuYang, Yao Xiao, Kai-Yun You, Lu-Ning Zhang, Xiao-Wen Lan, Xiao-Min Zhang, Fang-Yun Xie*. Validation and comparison of the 7th and 8th edition of AJCC staging systems for non-metastatic nasopharyngeal carcinoma, and proposed staging systems from Hong Kong, Guangzhou, and Guangxi. Oral Oncol 2017; 72: 65-72.(IF 4.794)

26.Pu-Yun OuYang, Lu-Ning Zhang, Yao Xiao, Xiao-Wen Lan, Xiao-Min Zhang, Jun Ma, Fang-Yun Xie*. Validation of published nomograms and accordingly individualized induction chemotherapy in nasopharyngeal carcinoma. Oral Oncol 2017;67:37-45.(IF 4.794)

27.Lu-Ning Zhang, Yuan-Hong Gao, Xiao-Wen Lan, Jie Tang, Pu-Yun OuYang, Fang-Yun Xie*. Effect of taxanes-based induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: A large scale propensity-matched study. Oral Oncol 2015;51:950-956(IF 4.794)

2023年10月11日